Detalhe da pesquisa
1.
Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine Development.
J Infect Dis
; 218(9): 1436-1446, 2018 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29800314
2.
Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans.
J Infect Dis
; 213(9): 1495-504, 2016 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26787651
3.
Norovirus vaccine against experimental human Norwalk Virus illness.
N Engl J Med
; 365(23): 2178-87, 2011 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22150036
4.
Interrogation of a live-attenuated enterotoxigenic Escherichia coli vaccine highlights features unique to wild-type infection.
NPJ Vaccines
; 4: 37, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31482013
5.
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.
J Clin Invest
; 128(8): 3298-3311, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29771685
6.
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.
Clin Vaccine Immunol
; 21(11): 1589-99, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25253665
7.
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severity.
J Clin Invest
; 129(7): 2980, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31259744
8.
The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.
Clin Vaccine Immunol
; 19(12): 1921-31, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23035175
9.
The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.
Vaccine
; 30(9): 1729-36, 2012 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22192849
10.
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
AIDS Res Hum Retroviruses
; 25(1): 103-14, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19108693
11.
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
J Acquir Immune Defic Syndr
; 44(2): 203-12, 2007 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17106277
12.
Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Virology
; 353(2): 451-62, 2006 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-16863657
13.
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
J Infect Dis
; 191(5): 654-65, 2005 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15688278
14.
HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood.
Vaccine
; 23(27): 3555-64, 2005 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15855014
15.
Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.
Vaccine
; 21(11-12): 1174-9, 2003 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-12559795
16.
Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.
J Acquir Immune Defic Syndr
; 37(3): 1385-92, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15483468
17.
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
J Infect Dis
; 188(2): 327-38, 2003 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12854090